|
The First nine months of this year they added a total of 34 million shares and most were added at a much higher price.
This last quarter they filed they added no shares at all and that leaves only 34 million shares ever sold below or at the pennies mark.
Most of the down volume this year has been on light shares and it is ready to race back up to at the least .005 this first quarter.
Company has not set a precedent of selling many shares and there are no filings suggesting any shares are really ready for sales.
I think most of the large owners will not do anything but buy shares from here back to the penny.
I have the shares listed below now and I also have the insiders shares on the last ten-k report.
It is close to what they have on the market and chart suggest they are much higher then a penny now for those shares.
It is just a matter of time we are back in the penny this new year and this next week we should test the .003 with a .0025 break in the picture.
There are over 51% or over 600 million shares owned by directors.
When they did the reverse merger at the higher price they sold 232 million shares to the market and investors in 2011.
They then added the 500 million shares also for the reverse for the new company.
I figure there are another 200 million shares tied up with the large buyers and I look for there only to be 30 to 40 million shares sold below the penny now.
Also note the Sysco has some shares and a contract to sell the service to there chain.
Huge Re-seller there with Sysco Icare selling to restaurants bars and other customers. They have a huge distribution across the whole US and will roll it out as the company can grow.
Below is the break down report of total shares and below that is the weekly chart for the year.
As of September 30, 2012, there were 1,202,889,520 shares of the Registrant's Common Stock outstanding.
On April 1, 2011, the Company entered into an agreement with iCare Marketing, Inc. (“iCare), a wholly owned subsidiary of Sysco Corporation (“Sysco”), whereby iCare will promote the Company’s product to Sysco’s customers. Under the agreement, the Company is committed to pay 5% of the gross revenues received from any Sysco customer, an integration fee, $250 per trade show event attended by the Company and an amount to be determined for additional promotions and marketing programs. The Company paid $50,000 of the integration fee in cash and the balance by issuing 15,861,372 shares of common stock which were valued at $22,205, using a price per share of $.0014, , which is the price per share applicable to the October 2011 issuances described in Note 5, above.. The integration fee has been recorded at $72,205 and is being amortized over the four-year life of the agreement. $16,765 has been recorded for amortization of the agreement during the year ended December 31, 2011.
As of September 30, 2012, there were 1,202,889,520 shares of the Registrant's Common Stock outstanding.
|
Name and Address
of Beneficial Owner
|
|
Nature and Amount
of Beneficial Ownership
of Common Stock
|
|
Percentage of Ownership 1
|
| |
|
|
|
|
|
Mark E. Astrom 2
|
|
5,000
|
|
0%
|
|
Christopher Carey
|
|
143,327,787
|
|
12.26%
|
|
Christopher Carey, Jr.
|
|
160,527,121 3
|
|
13.74%
|
|
Mary Weaver Carey
|
|
315,321,131 4
|
|
26.98%
|
|
Blazej Kesy
|
|
143,327,787
|
|
12.26%
|
|
All directors and executive
officers as a group (3 persons)
|
|
601,981,705
|
|
51.50%
|
1 0k report this last year. and we are nine m onths reported above
EYES ON THE GO, INC.
STATEMENT OF STOCKHOLDERS’ DEFICIENCY
| |
|
|
|
|
|
|
|
Additional
|
|
|
|
|
|
|
|
|
|
|
| |
|
COMMON STOCK
|
|
|
Paid-In
|
|
|
Subscription
|
|
|
Accumulated
|
|
|
|
|
| |
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
Receivable
|
|
|
Deficit
|
|
|
Total
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE – August 26, 2010 (Inception)
|
|
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued to founders
|
|
|
360,000,000
|
|
|
|
360
|
|
|
|
(360
|
)
|
|
|
|
|
|
|
-
|
|
|
|
-
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...
Continue Reading
The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...
Continue Reading
GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...
Continue Reading
Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...
Continue Reading
The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...
Continue Reading
The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...
Continue Reading
Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...
Continue Reading
Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...
Continue Reading
Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...
Continue Reading
Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...
Continue Reading
Top 5 Most Recently Viewed Articles
SAP Enhances Data Security with New Cloud Solutions SAP SE shares are experiencing a positive trend in premarket trading. Recently, SAP Canada introduced its innovative SAP Sovereign Cloud capabilities, which are designed to address the increasing demand from organizations for data sovereignty, robust security, and regulatory compliance. This pioneering solution enables...
Continue Reading
Corbus Pharmaceuticals Sees Significant Stock Drop Amid Market Responses Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) has recently faced a dramatic decline in its stock, plummeting by an alarming 60%. However, analysts are encouraging investors to view this as a potential buying opportunity. Firms like H.C. Wainwright and Oppenheimer have reaffirmed their buy...
Continue Reading
Manatt's Strategic Growth in Corporate Practice Manatt, Phelps & Phillips, LLP is making waves in the corporate legal landscape with its recent addition of Peter Tsirigotis, a seasoned investment funds partner. This move reflects the firm's commitment to expanding its financial services and corporate capabilities. Based in Washington, D.C., Tsirigotis brings a wealth of...
Continue Reading
Performance Share Units Vesting Announcement ISS A/S is proud to announce the significant milestone concerning its long-term incentive program (LTIP). As part of this initiative, a number of Performance Share Units (PSUs) have recently vested, leading to the delivery of ISS shares to key personnel within the company. This process, which emphasizes the company's commitment...
Continue Reading
Omnicom Boosts Dividend for Shareholders Omnicom, a renowned leader in marketing and sales, has officially announced an increase in its quarterly dividend to $0.80 per share. This enhancement reflects a significant increase in the company's commitment to its shareholders, offering both immediate rewards and a long-term strategy for growth. Dividend Increase Overview The...
Continue Reading
| |
